{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:17:10Z","timestamp":1771373830536,"version":"3.50.1"},"reference-count":43,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_med-2019-0063_s_006\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ifosfamide (IF) is a cytostatic that exhibits adverse nephrotoxic properties. Clinically, IF-induced nephrotoxicity takes various forms, depending on applied dose and length of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2019-0063_s_007\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of the study was to evaluate the two proteins: osteopontin (OP) and fatty acid binding protein (FABP), as markers of kidney function in rats treated with ifosfamide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2019-0063_s_008\">\n                    <jats:title>Material and Methods<\/jats:title>\n                    <jats:p>Rats receiving a single IF dose (250 mg\/kg b.w.; group 1) or treated with five consecutive IF doses administrated on following days (50mg\/kg b.w.; group 3), compared with control groups 2 and 4, respectively, were studied. Kidney function was assessed using classical (urea, creatinine) and novel (FABP, OP) laboratory parameters and by histopathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2019-0063_s_009\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Single IF dose administration resulted in significant total proteinuria with urinary concentrations and 24-hour excretions of both FABP and OP comparable to the appropriate control. In rats treated with five consecutive IF doses, the urinary concentrations and 24-hour excretion of both FABP and OP were significantly higher compared to the appropriate control. The development of cystitis was revealed in groups 1 and 3, which was not accompanied by significant histopathological kidney damage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2019-0063_s_010\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both OP and FABP may be useful laboratory markers of tubulopathy in the early stage of chronic nephrotoxicity of ifosfamide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2019-0063","type":"journal-article","created":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T05:05:40Z","timestamp":1564808740000},"page":"561-571","source":"Crossref","is-referenced-by-count":5,"title":["Osteopontin and fatty acid binding protein in ifosfamide-treated rats"],"prefix":"10.1515","volume":"14","author":[{"given":"\u0141ukasz","family":"Dobrek","sequence":"first","affiliation":[{"name":"Independent Researcher cooperating with Experimental and Innovative Medicine Centre , University Centre of Veterinary Medicine UJ-UR, University of Agriculture in Krakow , Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zbigniew","family":"Arent","sequence":"additional","affiliation":[{"name":"Independent Researcher cooperating with Experimental and Innovative Medicine Centre , University Centre of Veterinary Medicine UJ-UR, University of Agriculture in Krakow , Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaudia","family":"Nalik-Iwaniak","sequence":"additional","affiliation":[{"name":"Independent Researcher cooperating with Experimental and Innovative Medicine Centre , University Centre of Veterinary Medicine UJ-UR, University of Agriculture in Krakow , Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Fic","sequence":"additional","affiliation":[{"name":"Independent Researcher cooperating with Experimental and Innovative Medicine Centre , University Centre of Veterinary Medicine UJ-UR, University of Agriculture in Krakow , Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Kopa\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Human Physiology, Faculty of Medicine, University of Rzeszow , Rzeszow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"2026012107363617488_j_med-2019-0063_ref_001","doi-asserted-by":"crossref","unstructured":"Wang D, Wang H. Oxazaphosphorine bioactivation and detoxification. The role of xenobiotic receptors. Acta Pharm Sin B 2012; 2, 21 pages","DOI":"10.1016\/j.apsb.2012.02.004"},{"key":"2026012107363617488_j_med-2019-0063_ref_002","doi-asserted-by":"crossref","unstructured":"Sloderbach A, G\u00f3rska A, Sikorska M, Misiura K, H\u0142ado\u0144 B. Klasyczne oksazafosforiany \u2013 metabolizm i w\u0142a\u015bciwo\u015bci terapeutyczne (Classical oxazaphosphorines \u2013 metabolism and therapeutic properties \u2013 new implications). Postepy Hig Med Dosw (online) 2013; 67: 1235-1253. (in Polish)","DOI":"10.5604\/17322693.1079389"},{"key":"2026012107363617488_j_med-2019-0063_ref_003","doi-asserted-by":"crossref","unstructured":"Liang J, Huang M, Duan W, Yu XQ, Zhou S. Design of new oxazaphosphorine anticancer drugs. Curr Pharm Des 2007; 13: 963-978","DOI":"10.2174\/138161207780414296"},{"key":"2026012107363617488_j_med-2019-0063_ref_004","doi-asserted-by":"crossref","unstructured":"Zhang J, Tian Q, Zhu YZ, Xu AL, Zhou SF. Reversal of resistance to oxazaphosphorines. Curr Cancer Drug Targets 2006; 6: 385-407","DOI":"10.2174\/156800906777723967"},{"key":"2026012107363617488_j_med-2019-0063_ref_005","doi-asserted-by":"crossref","unstructured":"Furlanut M, Franceschi L. Pharmacology of ifosfamide. Oncology 2003; 65(suppl. 2): 2-6","DOI":"10.1159\/000073350"},{"key":"2026012107363617488_j_med-2019-0063_ref_006","doi-asserted-by":"crossref","unstructured":"Sharbaf FG, Farhangi H, Assadi F. Prevention of chemotherapy-induced nephrotoxicity in children with cancer. Int J Prev Med 2017; 8: 76","DOI":"10.4103\/ijpvm.IJPVM_40_17"},{"key":"2026012107363617488_j_med-2019-0063_ref_007","unstructured":"Thomas D, Zachariah S, Elamin AEE, Hashim ALO. Limitations of serum creatinine as a marker of renal function. Sch Acad J Pharm 2017; 6: 168-170"},{"key":"2026012107363617488_j_med-2019-0063_ref_008","unstructured":"Gowda S, Desai PB, Kulkarni SS, Hull VV, Math AAK, Vernekar SN. Markers of renal function tests. N Am J Med Sci 2010; 2: 170-173"},{"key":"2026012107363617488_j_med-2019-0063_ref_009","doi-asserted-by":"crossref","unstructured":"Lombi F, Muryan A, Canzonieri R, Trimarchi H. Biomarkers in acute kidney injury: evidence or paradigm? Nefrologia 2016; 36: 339-346","DOI":"10.1016\/j.nefroe.2016.10.006"},{"key":"2026012107363617488_j_med-2019-0063_ref_010","doi-asserted-by":"crossref","unstructured":"Alge JL, Arthur JM. Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications. Clin J Am Soc Nephrol 2015; 10: 147-155","DOI":"10.2215\/CJN.12191213"},{"key":"2026012107363617488_j_med-2019-0063_ref_011","unstructured":"Shen P, Li W, Jiang J, He L. Liver fatty acid binding protein protects renal function through down-regulation of oxidative stress in IgA nephropathy. Int J Clin Pathol 2017; 10: 1131-1139"},{"key":"2026012107363617488_j_med-2019-0063_ref_012","doi-asserted-by":"crossref","unstructured":"Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB. Osteopontin modulates angiotensin II\u2013induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009; 76: 32-43","DOI":"10.1038\/ki.2009.90"},{"key":"2026012107363617488_j_med-2019-0063_ref_013","doi-asserted-by":"crossref","unstructured":"Borner K, Kisro J, Bruggemann SK, Hagenah W, Peters SO, Wagner T. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo. Drugs Metab Dispos 2000; 28: 573-576","DOI":"10.1016\/S0090-9556(24)15102-1"},{"key":"2026012107363617488_j_med-2019-0063_ref_014","doi-asserted-by":"crossref","unstructured":"Mancini L, Payne GS, Dzik-Jurasz ASK, Leach LO. Ifosfamide pharmacokinetics and hepatobiliary uptake in vivo investigated using single- and double-resonance 31P MRS. Magn Reson Med 2003; 50: 249-255","DOI":"10.1002\/mrm.10540"},{"key":"2026012107363617488_j_med-2019-0063_ref_015","doi-asserted-by":"crossref","unstructured":"Sayed-Ahmed MM, Hafez MM, Aldelemy ML, Aleisa AM, Al-Rejaie SS, Al-Hosaini KA, Al-Harbi NO, Al-Harbi MM, Al-Shabanah OA. Downregulation of oxidative and nitrosative apoptotic signaling by L-carnitine in ifosfamide-induced Fanconi syndrome rat model. Oxid Med Cell Longev, Volume 2012, Article ID 696704, 9 pages","DOI":"10.1155\/2012\/696704"},{"key":"2026012107363617488_j_med-2019-0063_ref_016","doi-asserted-by":"crossref","unstructured":"Ozguven AA, Y\u0131lmaz O, Taneli F, Ulman C, Vatansever S, Onag A. Protective role of ketamine against hemorrhagic cystitis in rats receiving ifosfamide. Indian J Pharmacol 2014; 46: 147-151","DOI":"10.4103\/0253-7613.129301"},{"key":"2026012107363617488_j_med-2019-0063_ref_017","unstructured":"Charakterystyka produktu leczniczego Holoxan http:\/\/pub.rejestrymedyczne.csioz.gov.pl (accessed on 14. 02. 2019; in Polish)"},{"key":"2026012107363617488_j_med-2019-0063_ref_018","doi-asserted-by":"crossref","unstructured":"Garimella-Krovi S, Springate JE. Effect of glutathione depletion on ifosfamide nephrotoxicity in rats. Int J Biomed Sci 2008; 4: 171-174","DOI":"10.59566\/IJBS.2008.4171"},{"key":"2026012107363617488_j_med-2019-0063_ref_019","doi-asserted-by":"crossref","unstructured":"Chen N, Aleksa K, Woodland C, Rieder M, Koren G. N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. Br J Pharmacol 2008; 153: 1364-1372","DOI":"10.1038\/bjp.2008.15"},{"key":"2026012107363617488_j_med-2019-0063_ref_020","doi-asserted-by":"crossref","unstructured":"Lee G, Romih R, Zupancic D. Cystitis: from urothelial cell biology to clinical applications. BioMed Res Int 2014; Article ID 473536, 10 pages","DOI":"10.1155\/2014\/473536"},{"key":"2026012107363617488_j_med-2019-0063_ref_021","doi-asserted-by":"crossref","unstructured":"Lopez-Giacoman S, Madero M. Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol 2015; 4: 57-73","DOI":"10.5527\/wjn.v4.i1.57"},{"key":"2026012107363617488_j_med-2019-0063_ref_022","unstructured":"Dobrek \u0141, Skowron B, Baranowska A, Malska-Wo\u017aniak A, Thor P. Urinary kidney injury molecule-1 excretion in rats with experimental cystitis induced by oxazaphosphorines. Przegl Lek 2016; 73: 805-812"},{"key":"2026012107363617488_j_med-2019-0063_ref_023","doi-asserted-by":"crossref","unstructured":"Nissim I, Horyn O, Daikhin Y, Nissim I, Luhovyy B, Phillips PC, Yudkoff M. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res 2006; 66: 7824-7831","DOI":"10.1158\/0008-5472.CAN-06-1043"},{"key":"2026012107363617488_j_med-2019-0063_ref_024","doi-asserted-by":"crossref","unstructured":"Elfawy HA, Das B. Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: Etiologies and therapeutic strategies. Life Sci 2019; 218: 165-184","DOI":"10.1016\/j.lfs.2018.12.029"},{"key":"2026012107363617488_j_med-2019-0063_ref_025","doi-asserted-by":"crossref","unstructured":"Gueguen N, Desquiret-Dumas V, Leman G, Chupin S, Baron S, Nivet-Antoine V, Vessi\u00e8res E, Ayer A, Henrion D, Lenaers G, Reynier P, Procaccio V. Resveratrol directly binds to mitochondrial complex I and increases oxidative stress in brain mitochondria of aged mice. PLOS One 2015; 10: e0144290","DOI":"10.1371\/journal.pone.0144290"},{"key":"2026012107363617488_j_med-2019-0063_ref_026","doi-asserted-by":"crossref","unstructured":"Ruggiero A , Ferrara P, Attina G, Rizzo D, Riccardi R. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol 2017; 83: 2605-2614","DOI":"10.1111\/bcp.13388"},{"key":"2026012107363617488_j_med-2019-0063_ref_027","doi-asserted-by":"crossref","unstructured":"Fuchs TC, Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity \u2013 an overview for applied toxicology. The AAPS Journal 2011; 13: 615-631","DOI":"10.1208\/s12248-011-9301-x"},{"key":"2026012107363617488_j_med-2019-0063_ref_028","doi-asserted-by":"crossref","unstructured":"Rysz J, Gluba-Brz\u00f3zka A, Franczyk B, Jab\u0142onowski Z, Cia\u0142kowska-Rysz A. Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Int J Mol Sci 2017; 18: 1702, 17 pages","DOI":"10.3390\/ijms18081702"},{"key":"2026012107363617488_j_med-2019-0063_ref_029","doi-asserted-by":"crossref","unstructured":"Xie HG, Wang SK, Cao CC, Harpur E. Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction. Pharmacol Ther 2013; 137: 100-107","DOI":"10.1016\/j.pharmthera.2012.09.004"},{"key":"2026012107363617488_j_med-2019-0063_ref_030","doi-asserted-by":"crossref","unstructured":"Tesch GH. Review: Serum and urine biomarkers of kidney disease: a pathophysiological perspective. Nephrology 2010; 15: 609-616","DOI":"10.1111\/j.1440-1797.2010.01361.x"},{"key":"2026012107363617488_j_med-2019-0063_ref_031","doi-asserted-by":"crossref","unstructured":"Gajda AM, Storch J. Enterocyte fatty acid-binding proteins (FABPs): different functions of liver and intestinal FABPs in the intestine. Prostaglandins Leukot Essent Fatty Acids 2015; 93: 9-16","DOI":"10.1016\/j.plefa.2014.10.001"},{"key":"2026012107363617488_j_med-2019-0063_ref_032","doi-asserted-by":"crossref","unstructured":"Charlton JR, Portilla D, Okusa MD. A basic science view of acute kidney injury biomarkers. Nephrol Dial Transplant 2014; 29: 1301-1311","DOI":"10.1093\/ndt\/gft510"},{"key":"2026012107363617488_j_med-2019-0063_ref_033","doi-asserted-by":"crossref","unstructured":"Chacko S, Haseeb S, Glover BM, Wallbridge D, Harper A. The role of biomarkers in the diagnosis and risk stratification of acute coronary syndrome. Future Sci OA 2017; 4: FSO251","DOI":"10.4155\/fsoa-2017-0036"},{"key":"2026012107363617488_j_med-2019-0063_ref_034","unstructured":"Erenler AK, Yardan T, Duran L, Baydin A. Usefulness of heart-type fatty acid binding protein in the emergency department. J Pak Med Assoc 2013; 63: 1176-1181"},{"key":"2026012107363617488_j_med-2019-0063_ref_035","doi-asserted-by":"crossref","unstructured":"Hunter GK. Role of osteopontin in modulation of hydroxyapatite formation. Calcif Tissue Int 2013; 93: 348-354","DOI":"10.1007\/s00223-013-9698-6"},{"key":"2026012107363617488_j_med-2019-0063_ref_036","doi-asserted-by":"crossref","unstructured":"Yasui T, Okada A, Hamamoto S, Ando R, Taguchi K, Tozawa K, Kohri K. Pathophysiology-based treatment of urolithiasis. Int J Urol 2017; 24: 32-38","DOI":"10.1111\/iju.13187"},{"key":"2026012107363617488_j_med-2019-0063_ref_037","doi-asserted-by":"crossref","unstructured":"Rittling SR. Osteopontin in macrophage function. Expert Rev Mol Med 2011; 13: e15","DOI":"10.1017\/S1462399411001839"},{"key":"2026012107363617488_j_med-2019-0063_ref_038","doi-asserted-by":"crossref","unstructured":"Lim AI, Tang SCW, Lai KN, Leung JCK. Kidney injury molecule-1: more than just an injury marker of tubular epithelial cells? J Cell Physiol 2013; 228: 917-924","DOI":"10.1002\/jcp.24267"},{"key":"2026012107363617488_j_med-2019-0063_ref_039","doi-asserted-by":"crossref","unstructured":"Yin C, Wang N. Kidney injury molecule-1 in kidney disease. Ren Fail 2016; 38: 1567-1573","DOI":"10.1080\/0886022X.2016.1193816"},{"key":"2026012107363617488_j_med-2019-0063_ref_040","doi-asserted-by":"crossref","unstructured":"Barrera-Chimal J, Bobadilla NA. Are recently reported biomarkers helpful for early and accurate diagnosis of acute kidney injury? Biomarkers 2012; 17: 385-393","DOI":"10.3109\/1354750X.2012.680070"},{"key":"2026012107363617488_j_med-2019-0063_ref_041","doi-asserted-by":"crossref","unstructured":"Kashani K, Kellum JA. Novel biomarkers indicating repair or progression after acute kidney injury. Curr Opin Nephrol Hypertens 2015; 24: 21-27","DOI":"10.1097\/MNH.0000000000000090"},{"key":"2026012107363617488_j_med-2019-0063_ref_042","doi-asserted-by":"crossref","unstructured":"Kashani K, Cheungpasitporn W, Ronco C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption. Clin Chem Lab Med 2017; 55: 1074-1089","DOI":"10.1515\/cclm-2016-0973"},{"key":"2026012107363617488_j_med-2019-0063_ref_043","doi-asserted-by":"crossref","unstructured":"Kaleta B. The role of osteopontin in kidney diseases. Inflamm Res 2019; 68(2): 93-102","DOI":"10.1007\/s00011-018-1200-5"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/med\/14\/1\/article-p561.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2019-0063\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2019-0063\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:37:56Z","timestamp":1768981076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2019-0063\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,16]]},"published-print":{"date-parts":[[2019,1,16]]}},"alternative-id":["10.1515\/med-2019-0063"],"URL":"https:\/\/doi.org\/10.1515\/med-2019-0063","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,1]]}}}